ON WILLEBRAND DISEASE (vWD) is the most V common bleeding disorder of humans.' The phenotypic expression of this condition ranges from very mild to life-threatening hemorrhaging. Patients with vWD are usually divided into three groups. Type I vWD is characterized by quantitative deficiency of von Willebrand factor (vWF) and by autosomal dominant inheritance. Type 111 vWD is characterized by a virtual absence of vWF and by autosomal recessive inheritance. Type I1 vWD is characterized by normal to decreased plasma levels of vWF and the residual vWF is functionally abnormal. In most type I1 vanants, SDS-agarose gel electrophoresis shows a loss of high molecular weight multimers, thereby distinguishing these variants from type I and type 111 vWD. The subtypes (A to H) of type I1 vWD are distinguished on the basis of specific functional defects or by details of the multimer pattern.' Type IIC vWD was described in 1982 by Ruggeri and colleagues3 in a patient with low vWFAg and ristocetin cofactor (RCoF) activity and was inherited as an autosomal recessive disorder. By multimeric analysis, the repeating triplet pattern of normal plasma vWF was replaced by one major band with a single faint intervening band, and the smallest multimer was relatively increased. Four unrelated families have been reported to be affected by recessive vWD with a similar phenotype:-'Some variation was observed in the number of intervening bands for plasma vWF multimer patterns,'-' and in the degree of abnormality for platelet vWF multimer pattern^,',^ suggesting that vWD type IIC may be heterogeneous. The molecular basis for the recessive type IIC variants is not known.
V common bleeding disorder of humans.' The phenotypic expression of this condition ranges from very mild to life-threatening hemorrhaging. Patients with vWD are usually divided into three groups. Type I vWD is characterized by quantitative deficiency of von Willebrand factor (vWF) and by autosomal dominant inheritance. Type 111 vWD is characterized by a virtual absence of vWF and by autosomal recessive inheritance. Type I1 vWD is characterized by normal to decreased plasma levels of vWF and the residual vWF is functionally abnormal. In most type I1 vanants, SDS-agarose gel electrophoresis shows a loss of high molecular weight multimers, thereby distinguishing these variants from type I and type 111 vWD. The subtypes (A to H) of type I1 vWD are distinguished on the basis of specific functional defects or by details of the multimer pattern. ' Type IIC vWD was described in 1982 by Ruggeri and colleagues3 in a patient with low vWFAg and ristocetin cofactor (RCoF) activity and was inherited as an autosomal recessive disorder. By multimeric analysis, the repeating triplet pattern of normal plasma vWF was replaced by one major band with a single faint intervening band, and the smallest multimer was relatively increased. Four unrelated families have been reported to be affected by recessive vWD with a similar phenotype:-'Some variation was observed in the number of intervening bands for plasma vWF multimer patterns,'-' and in the degree of abnormality for platelet vWF multimer pattern^,',^ suggesting that vWD type IIC may be heterogeneous. The molecular basis for the recessive type IIC variants is not known.
Within a pedigree comprising 16 individuals, spanning four generations, we have identified 6 patients with vWD in which the multimeric analysis of plasma vWF is consistent with the type IIC phenotype. In contrast to the reported cases classified as vWD type IIC, this new variant is inherited as an autosomal dominant disorder and all affected persons in this family have markedly increased plasma vWFAg levels with slightly reduced plasma vWF RCoF. In addition, the platelet vWF multimeric pattern demonstrates higher molecular weight multimers than previously noted in propositi with recessive vWD type IIC.
Detailed genetic analysis strongly suggests that this dominant type IIC variant is caused by a mutation within, or closely linked to, the ~WFgene. By DNA sequencing, mutations in exon 28 of the vWF gene were excluded, which indicates that the mechanism for this new variant differs from that causing vWD types IIA and IIB.
MATERIALS, METHODS, AND CASE HISTORY

Materials and Methods
Collection and handling of blood samples. For phenotypic studies, blood samples were collected in 1/10 volume of 3.8% sodium citrate with or without a protease inhibitor cocktail consisting of 0.1 mmol/L leupeptin, 5.0 mmol/L EDTA, and 6 mmol/L N-ethylmaleimide (Sigma, St Louis, MO). For genetic studies, blood samples were anticoagulated with EDTA. Platelet lysates were prepared es-hour at 37°C. Platelet counts and mean platelet volume (MPV) were determined with a Coulter STKR (Coulter Corp, Hialeah, FL).
Ivy bleeding times (BT) were performed using a Surgicutt device (International Technidyne Corp, Edison, NJ). Ristocetin-induced platelet agglutination (RIPA) and RCoF activity assays were performed by standard aggregometric methods using ristocetin concentrations from 0.4 to 1.5 mg/mL and 1 . O mg/mL, respectively. For the RCoF assay, lyophilized platelets were from Bio/Data Corp, and a CAP (College of American Pathologists, Chicago, IL) reference vWF preparation was used for establishing a standard curve. Botrocetin and lyophilized platelets for botrocetin cofactor assay were kindly provided by American Diagnostica, Inc (Greenwich, CT). The assay was performed on a PAP-4 aggregometer (Bio/Data Corp, Horsham, PA) using botrocetin at a final concentration of 5 U/mL, lyophilized platelets adjusted to 8 X 108/L, and normal pooled plasma (30 donors) for calibration. vWF:Ag was determined with an ELISA kit (Diagnostica Stago, American Bioproducts Co, Parsippany, NJ) and also by the method of Laurell" using a polyclonal rabbit antihuman vWF antibody (Diagnostica Stago).
Electrophoretic analysis of v WF structiire. Multimeric analysis of plasma and platelet vWF was performed by two methods': (1) autoradiography, using an F(ab'), rabbit anti-human vWF antibody (Diagnostica Stago) and (2) electroblotting, using the same polyclonal antibody as for the Laurell method and a horseradish peroxidase-conjugated goat anti-rabbit affinity-purified IgG (CalBiochem, La Jolla, CA) as the secondary antibody.
LGT VI1 agarose (Sigma) was used at concentrations of 1.4% or 2.0% as indicated.
Subunit composition of plasma vWF was determined in a gel system similar to that used for multimer analysis except that samples contained 5% 2mercaptoethanol and were heated for I minute at 100°C. 5.0% NuSieve GTG agarose was used for the running gel and I .O% IsoGel was used for the stacking gel (FMC Corp, Rockland, ME).
Activated partial thromboplastin time (APTT) and one-stage factor VIII:C assays were performed on a Coag-AMate X2 (Organon Teknika, Durham, NC) using Organon Teknika reagents and reference plasmas. Factor VII1:C was also assayed by a chromogenic substrate method using a commercially prepared kit with substrate CBS 48.03 (Diagnostica Stago). Analysis of PCR-amplified DNA. Genomic DNA was prepared from peripheral blood leukocytes.'' Polymerase chain reaction (PCR)** was performed using a Perkin Elmer-Cetus (Norwalk, CT) DNA Thermal Cycler as previously described." Primers used for amplification of exon 28 were No. 226, TGC GAA TAT GGA ACT CAT TG; No. 227a, CCG ATC CTT CCA GGA CGA AC; and No. 375a, TCT TGG CAG ATG CAT GTA GC. PCR-amplified fragments of exon 28 using primers 226 and 227a were digested with BstEII (New England Biolabs, Beverly, MA), electrophoresed on a 1 % agarose gel, and visualized by staining with ethidium bromide. Analysis of intron 40 variable number of tandem repeat (VNTR) polymorphism was performed as previously des~ribed.'~.'~ Primers used for intron 40 were No. 474, AGC TAT ATA TCT ATT TAT CAT and No. 475a, AGA TAC ATA CAT AGA TAT AGG. DNA subcloning and sequencing were performed as previously described.I6
A.w2j6 of'vWF.function and concentration.
Other assays.
Case History
The proband of family M, a 46-year-old white woman. was re- In November 1990, a fine-needle aspiration ofthe thyroid was successfully performed with cryoprecipitate coverage. The patient has occasional gingival bleeding, menorrhagia, and prolonged bleeding from minor skin lacerations. Since puberty she has had epistaxis requiring nasal packing on numerous (>IO) occasions. Transfusions of unknown type were required for bleeding following both a tonsillectomy and appendectomy at age 5. The patient has had several teeth extracted uneventfully; however, removal of a wisdom tooth at age 25 resulted in the formation of a large facial hematoma. The patient has had seven pregnancies, of which three ended in miscarriage. Two vaginal deliveries were uneventful. Two cesarian sections were complicated by bleeding that required blood transfusions. One month following the delivery ofher last child, she experienced excessive uterine bleeding requiring blood transfusions. No transfusions were needed for a subsequent hysterectomy.
The pedigree of family M is shown in Fig 1. The proband (11-3) and five other affected family members have vWFAg levels greater than 1 S O U/mL. The proband's mother (I-I ) had a history of menorrhagia and of bleeding after each of five vaginal deliveries but never received blood products. The proband has three brothers with uneventful histories. A sister has a history of menorrhagia, occasional epistaxis that was particularly severe after an automobile accident, and bleeding after vaginal delivery treated with platelet transfusion. The proband has three surviving children; each has gingival bleeding and both daughters have menorrhagia.
RESULTS
Values for BT, VIII:C, vWFAg, and RCoF are summarized in Table 1 . The six affected family members had prolonged bleeding times (> 15 minutes) and normal platelet counts. These individuals had markedly elevated plasma vWF:Ag levels by ELISA and also by the Laurell technique (data not shown). Plasma RCoF activity was variable among the six affected members ranging from low to within normal limits; however, the ratio of vWFAg to RCoF was -4.6: 1 for the affected members compared with -I .2: 1 for the unaffected family members. All individuals were AB0 blood group type 0 except 11-4, 111-1, and 111-4, who were type A. The six affected family members had normal V1II:C levels, although the ratio ofvWFAg to VII1:C was increased (-2.3:l). RIPA with concentrations of 0.8 to 1.5 mg/mL ristocetin was normal in all tested individuals, with no enhanced responsiveness to low-dose ristocetin (0.4 mg/mL). Plasma botrocetin cofactor activity was 58% and 78% for 11-3 and 111-1, respectively. Representative data for platelet vWF from three affected members (11-3,III-l, 111-3) showed platelet vWF:Ag levels above the normal range and normal platelet RCoF activity. Platelet vWF from 111-1 demonstrated 35% botrocetin cofactor activity.
For the six affected individuals, analysis of plasma vWF
For LGT) agarose gels (Fig 2A) revealed loss of the highest molecular weight multimers, no intervening bands, and an increase in the smallest multimer, with the latter two findings also observed using 2%
LGT agarose gels (data not shown). In Fig 2B , platelet vWF from representative affected family members, in an intermediate resolution gel, clearly demonstrates the presence of high molecular weight multimers that are comparable to normal plasma but not to normal platelet vWF. Densitometric scans (data not shown) showed high molecular weight multimers totaling 58% and 50% for normal platelet vWF and IIC platelet vWF, respectively. Gels of lower poiosity (2.0% agarose, data not shown) consistently disclosed an intervening band between multimers 1 and 2 as well as an increase in staining intensity of lower multimers relative to normal platelet vWF. These data suggest either that limited proteolysis occurs in vivo or that multimer assembly is abnormal in this vWD variant. 
C+T-C+T-
The subunit composition of plasma vWF from the proband (11-3) and her affected daughter (111-1) was compared with that of normal plasma vWF and vWF from an individual with type IIA vWD. Both affected patients demonstrated proteolytic fragments comparable to those found in normal plasma vWF and type IIA vWF (data not shown).
Two marker systems were used to investigate linkage of the vWD phenotype to the vWF gene in this family. One system exploits a highly polymorphic tetranucleotide (ATCT), repeat within intron 40. 15 In Fig 3, the observed PCR product sizes are designated a to d. The second system is a C/T polymorphism in exon 28 at nucleotide 464 1 numbered from the initiation codon. This polymorphism is detected by digestion with the enzyme BstEIII7 that cuts the DNA (indicated by +)if C is present but does not (indicated by -) if T is present. For 111-4, plasma samples were available for phenotypic characterization (Table I) , but blood cells for DNA isolation could not be obtained. All analyzed matings were informative and the results are consistent with linkage between the aC haplotype (Fig I ) and the type IIC phenotype (lod = 2. I , 0 = 0.00). The genotype of 1-2. who was not available for study. is inferred to be bT/cC. In an attempt to identify the causative mutation, regions of the vWF gene from patient 111-3 were subcloned and sequenced. Clones for both alleles were identified on the basis of heterozygosity for known DNA sequence polymorphisms. No candidate mutations were found for either allele in exons 4 to 5. exons 14 to IS. or exons 28 to 3 I. In particular. mutations in exon 28 known to cause vWD types IIA, IIB. and Bt8 were not present (data not shown).
DISCUSSION
The laboratory studies of the proband showed a disparity between vWFAgand RCoFand an absence ofhigh molecular weight vWF multimers. The normal triplet structure of the plasma vWF multimer pattern was replaced by a single band and the smallest multimer was accentuated (Fig 2h) . This pattern resembles that reported for vWD types IIC.F7 and IIE"? it is distinguished from type IIE by the prominence ofthe smallest multimer."On the basis ofthe plasma vWF multimer pattern. the disorder in family M is most similar to vWD type IIC.
The cases of vWD type IIC reported to date** show some phenotypic heterogeneity (Table 2 ). Common features include low levels of vWFAg. even lower RCoF activity, a h sent RIPA, and apparently autosomal recessive inheritance. Howevcr. differences are present among the vWF multimer patterns. Plasma vWF multimers consistently show an increase in the smallest multimer. but some patients show an absence of intervening bands5-' and others show a single faint intervening
The platelet vWF multimer pattern is more variable. For some patients, it appears to be identical to plasma vWF,'.~ but in others. there are differ- -4 11-3 III-I ID-3 II-2 1 -1 It-6 11-5 III-5 II-6 118-1 In contrast to other patients with vWD type IIC, affected members of family M have markedly elevated levels of vWF antigen (Table 2) . To exclude the possibility that the high antigen levels were not representative of the phenotype, several affected individuals were tested on multiple occasions and consistently demonstrated these findings. For affected members of family M, vWF function as determined by the ristocetin cofactor assay was borderline normal to low but significantly higher than values reported for other type IIC propositi. Although V1II:C levels were normal in family M, the ratio of VII1:C to vWFAg was low; administration of DDAVP to the proband increased this ratio into the normal range.
In the plasma of normal individuals or of patients with vWD types IIA or IIB, vWF consists mostly of the intact 250-Kd subunit but also contains proteolytic fragments of 189,176, and 140 Kd.I9 Several other variants with aberrant structure of individual multimers show markedly decreased amounts of these proteolytic fragments, particularly vWD types IIC (Swedish proband), IID, and IIE.19 In contrast, plasma vWF from two affected members of family M demonstrates the presence of fragments similar to those found in normal plasma vWF (data not shown). Thus, a marked decrease in intervening or satellite multimer species (Fig 2A) does not necessarily provide evidence for decreased subunit proteolysis.
Genetic analysis of family M showed complete concordance between intragenic vWF polymorphisms and the vWD phenotype, and this is consistent with a mutation in the vWF gene. If there is a single intragenic mutation, the mechanism by which it causes both defective multimer structure and high vWF:Ag levels is not obvious. In principle, the decrease in large multimers might be caused by impaired biosynthesis or by enhanced proteolysis. Our studies of plasma and platelet vWF do not provide clear evidence for either mechanism, and no explanation for the high vWF:Ag levels is apparent. One possibility is that the mutation could facilitate the transport of vWF through the endoplasmic reticulum, a process that is unusually prolonged for normal vWF.~' By reducing intracellular degradation or storage, such an effect could thereby increase the rate of vWF secretion.
The vWF gene of the proband was examined for mutations that might disrupt multimer biosynthesis or increase multimer degradation. The vWF propeptide is proposed to catalyze vWF multimer Segments of the vWF propeptide that are encoded by exons 4 and 5 (D1 domain) and exons 14 and 15 (D2 domain)16 show similarity to sequences in protein disulfide isomerase, and mutagenesis of these regions abolishes multimer formation.23 By DNA sequencing of PCR products, mutations within these sequences were excluded (data not shown). Similarly, of the mutations that cause vWD type IIA, some impair multimer formation and others increase sensitivity to proteolytic degradation.' By DNA sequencing, mutations were excluded in exons 28 to 3 1 (data not shown); these regions that encode for domains A 1 and A2 of the mature protein include all of the currently known mutations that cause vWD type IIA, as well as those that cause vWD types IIB and B.l* Thus, the molecular basis of vWD in family M is different from these previously characterized variants, which suggests that the pathophysiologic mechanism also is different.
To our knowledge, this is the first report of a qualitative defect of vWF that is associated with elevated levels of vWFAg. The unique combination of autosomal dominant inheritance, type IIC-like multimer pattern, and high vWF:Ag appears to represent a new variant of type I1 vWD.
Until classification can be based on either pathophysiologic mechanism or genetic defect, we propose to designate this new variant as vWD type IIC Miami to avoid the addition of new terms to the present nomenclature.
